1[1]Ridker PM,Rifai N,Pfeffer MA,et al.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events (CARE) Investigators[J].Circulation,1998,98(9):839-844
2[2]Marketou ME,Zacharis EA,Mkitovil D,et al.Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects[J].Angiology,2006,57(2):211-218
3[3]Devaraj S,Chan E,Jialal I.Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome[J].J Clin Endocr Metab,2006,91(11):4489-4496
4[4]Ridker PM,Rifai N,Pfeffer MA,et al.Long-term effect of pravastatin on plasma concentration of C-reactive protein[J].Circulation,1999,100(3):230-235
5[5]Blake GJ,Ridker PM.Novel clinical markers of vascular wall inflammation[J].Circ Res,2001,89(9):763-771
6[6]Seljeflot I,Tonstad S,Hjermann I,et al.Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease[J].Atherosclerosis,2002,162(1):179-185
7[7]Romano M,Mezzetti A,Marulli C,et al.Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients:role of nitric oxide[J].J Invest Med,2000,48(3):183-189
8[8]Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on C-reactive protein levels-The Pravastatin Inflammation/CRP Evaluation (PRINCE):a randomized trial and cohort study[J].JAMA,2001,286(1):64-70
9[9]Weitz-Schmidt G,Welzenbach K,Brinkmann V,et al.Statin selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site[J].Nature Med,2001,7(6):687-692
10[10]Marchesi S,Lupattelli G,Siepi D,et al.Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women[J].J Cardiovasc Pharm,2000,36(5):617-621
